Search

Your search keyword '"Topcu, Atakan"' showing total 30 results
Start Over Author "Topcu, Atakan"
30 results on '"Topcu, Atakan"'

4. Vicinity Effects of Field Free Point on the Relaxation Behavior of MNPs

Author

Topcu, Atakan, Alpman, Asli, Utkur, Mustafa, and Saritas, Emine Ulku

Subjects
Electrical Engineering and Systems Science - Signal Processing, Physics - Medical Physics
Abstract

In Magnetic Particle Imaging (MPI), the distribution of magnetic nanoparticles (MNPs) is imaged by moving a field free point (FFP) in space. All MNPs in close vicinity of the FFP contribute to the signal induced on the receive coil. The relaxation behavior of these MNPs are subject to a DC field due to the selection field (SF). In this work, we investigate the effects of the DC field on the relaxation behavior of the MNPs, with the goal of understanding the differences between the measured relaxations in Magnetic Particle Spectrometer (MPS) setups vs. MPI scanners.

Published
2021

5. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Author

Gursoy, Pınar, Tatli, Ali Murat, Erdem, Dilek, Goker, Erdem, Celik, Emir, Demirci, Nebi Serkan, Sakin, Abdullah, Atci, Muhammed Mustafa, Bayram, Ertuğrul, Telli, Tuğba Akın, Bilgin, Burak, Bilici, Ahmet, Akangunduz, Baran, Balli, Sevinç, Demirkazik, Ahmet, Selçukbiricik, Fatih, Menekse, Serkan, Cavdar, Eyyüp, Ozturk, Akın, Bekmez, Esma Türkmen, Turhal, Serdal, Kilickap, Sadettin, Yildirim, Hasan Çağrı, Oyan, Başak, Aksoy, Asude, Turkoz, Fatma Paksoy, Kut, Engin, Katgi, Nuran, Sakalar, Teoman, Akyol, Murat, Ellez, Halil İbrahim, Topcu, Atakan, Erdoğan, Atike Pınar, Pilanci, Kezban Nur, Hedem, Engin, Arak, Hacı, Akdeniz, Nadiye, Alan, Özkan, Yapar, Burcu, Nart, Deniz, and Yumuk, Perran Fulden

Published
2023
Full Text
View/download PDF

8. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Author

Goktas Aydin, Sabin, primary, Kavak, Engin Eren, additional, Topcu, Atakan, additional, Bayramgil, Ayberk, additional, Akgul, Fahri, additional, Kahraman, Seda, additional, Aykan, Musa Baris, additional, Altıntas, Yunus Emre, additional, Helvaci, Kaan, additional, Urun, Yuksel, additional, Bilici, Ahmet, additional, Seker, Mesut, additional, Sendur, Mehmet Ali Nahit, additional, Olmez, Omer Fatih, additional, Acikgoz, Ozgur, additional, and Cicin, Irfan, additional

Published
2023
Full Text
View/download PDF

9. The Correlation Between Skeletal Muscle Index and Anxiety in Patients with Lung Cancer on the First Day of Chemotherapy

Author

Topcu, Atakan, primary, Yurtsever, Ismail, additional, Isleyen, Zehra Sucuoglu, additional, Besiroglu, Mehmet, additional, Yasin, Ayse Irem, additional, Topcu, Zeynep Alaca, additional, Shbair, Abdallah TM, additional, Toluk, Ozlem, additional, Simsek, Melih, additional, Seker, Mesut, additional, and Turk, Haci Mehmet, additional

Published
2023
Full Text
View/download PDF

13. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Author

Goktas Aydin, Sabin, primary, Cakan Demirel, Burcin, additional, Bilici, Ahmet, additional, Topcu, Atakan, additional, Aykan, Musa Barış, additional, Kahraman, Seda, additional, Akbıyık, Ilgın, additional, Atci, Muhammed Mustafa, additional, Olmez, Omer Fatih, additional, Yaren, Arzu, additional, Sendur, Mehmet Ali Nahit, additional, Geredeli, Caglayan, additional, Seker, Mesut, additional, Urun, Yuksel, additional, Karadurmus, Nuri, additional, and Aydin, Ahmet, additional

Published
2022
Full Text
View/download PDF

14. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data.

Author

Topcu, Atakan, Besiroglu, Mehmet, Atci, Muhammed Mustafa, Secmeler, Saban, Ayhan, Murat, Ozkan, Metin, Bozkurt, Oktay, Urakci, Zuhat, Ay, Seval, Geredeli, Caglayan, Yasin, Ayse Irem, Pasin, Ozge, and Turk, Haci Mehmet

Subjects
THERAPEUTIC use of antineoplastic agents, STOMACH tumors, STATISTICS, FOLINIC acid, CONFIDENCE intervals, ONCOGENES, TRASTUZUMAB, LOG-rank test, METASTASIS, RETROSPECTIVE studies, IRINOTECAN, TREATMENT failure, TREATMENT effectiveness, PEARSON correlation (Statistics), FLUOROURACIL, QUALITATIVE research, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, KAPLAN-Meier estimator, CHI-squared test, DATA analysis software, PACLITAXEL, PROPORTIONAL hazards models
Abstract

Objectives: To compare the second-line treatments on survival after trastuzumab failure in HER2-positive metastatic gastric cancer. Methods: We retrospectively included 57 patients. Of whom, 32 (56%) received paclitaxel, whereas 25 (44%) received 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI). We analyzed the patient characteristics, and survival outcomes of the second-line treatment. Results: The median PFS was 3.5 months in the paclitaxel-group and 4.8 months in the FOLFIRI-group (p=0.569). The median overall survival (OS) was 6.0 months in paclitaxel-group and 11.0 months in FOLFIRI-group (p=0.410). FOLFIRI provided a significant OS advantage over paclitaxel in patients with grade 3 tumors or who did not have an objective first-line treatment response. Conclusion: FOLFIRI may be recommended as a preferred option over paclitaxel in patients with these identified risk factors. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Author

Gursoy, Pınar, primary, Tatli, Ali Murat, additional, Erdem, Dilek, additional, Goker, Erdem, additional, Celik, Emir, additional, Demirci, Nebi Serkan, additional, Sakin, Abdullah, additional, Atci, Muhammed Mustafa, additional, Bayram, Ertuğrul, additional, Telli, Tuğba Akın, additional, Bilgin, Burak, additional, Bilici, Ahmet, additional, Akangunduz, Baran, additional, Balli, Sevinç, additional, Demirkazik, Ahmet, additional, Selçukbiricik, Fatih, additional, Menekse, Serkan, additional, Cavdar, Eyyüp, additional, Ozturk, Akın, additional, Bekmez, Esma Türkmen, additional, Turhal, Serdal, additional, Kilickap, Sadettin, additional, Yildirim, Hasan Çağrı, additional, Oyan, Başak, additional, Aksoy, Asude, additional, Turkoz, Fatma Paksoy, additional, Kut, Engin, additional, Katgi, Nuran, additional, Sakalar, Teoman, additional, Akyol, Murat, additional, Ellez, Halil İbrahim, additional, Topcu, Atakan, additional, Erdoğan, Atike Pınar, additional, Pilanci, Kezban Nur, additional, Hedem, Engin, additional, Arak, Hacı, additional, Akdeniz, Nadiye, additional, Alan, Özkan, additional, Yapar, Burcu, additional, Nart, Deniz, additional, and Yumuk, Perran Fulden, additional

Published
2022
Full Text
View/download PDF

17. Real Life Comparison of Afatinib and Erlotinib in Non-small Cell Lung Cancer With Rare EGFR Exon 18 and Exon 20 Mutations: a Turkish Oncology Group (TOG) Study.

Author

Gürsoy, Pınar, primary, Tatlı, Ali Murat, additional, Erdem, Dilek, additional, Goker, Erdem, additional, Çelik, Emir, additional, Demirci, Nebi Serkan, additional, Sakin, Abdullah, additional, Atçı, Muhammed Mustafa, additional, Bayram, Ertuğrul, additional, Telli, Tuğba Akın, additional, Bilgin, Burak, additional, Bilici, Ahmet, additional, Akagündüz, Baran, additional, Ballı, Sevinç, additional, Demirkazık, Ahmet, additional, Selcukbiricik, Fatıh, additional, Menekşe, Serkan, additional, Cavdar, Eyyup, additional, Öztürk, Akın, additional, Bekmez, Esma Türkmen, additional, Turhal, Serdal, additional, Kılıçkap, Saadettin, additional, Yıldırım, Hasan Çağrı, additional, Oyan, Başak, additional, Aksoy, Asude, additional, TURKOZ, Fatma Paksoy, additional, Kut, Engin, additional, Katgı, Nuran, additional, Sakalar, Teoman, additional, Akyol, Murat, additional, Ellez, Halil İbrahim, additional, Topcu, Atakan, additional, Erdoğan, Atike Pınar, additional, Pilancı, Kezban Nur, additional, Hedem, Engin, additional, Arak, Hacı, additional, Akdeniz, Nadiye, additional, Alan, Özkan, additional, Yapar, Burcu, additional, Nart, Deniz, additional, and Yumuk, Perran Fulden, additional

Published
2021
Full Text
View/download PDF

19. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer

Author

Topcu, Atakan, primary, Atci, Muhammed Mustafa, additional, Secmeler, Saban, additional, Besiroglu, Mehmet, additional, Ayhan, Murat, additional, Ozkan, Metin, additional, Bozkurt, Oktay, additional, Urakci, Zuhat, additional, Ay, Seval, additional, Geredeli, Caglayan, additional, Yasin, Ayse Irem, additional, and Turk, Haci Mehmet, additional

Published
2021
Full Text
View/download PDF

21. sj-pdf-1-opp-10.1177_10781552211027931 - Supplemental material for A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer

Author

Topcu, Atakan, Yasin, Ayse Irem, Shbair, Abdallah TM, Besiroglu, Mehmet, Simsek, Melih, Sucuoglu, Zehra, Yurtsever, Ismail, Gucin, Zuhal, Seker, Mesut, and Turk, Haci Mehmet

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-1-opp-10.1177_10781552211027931 for A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer by Atakan Topcu, Ayse Irem Yasin, Abdallah TM Shbair, Mehmet Besiroglu, Melih Simsek, Zehra Sucuoglu, Ismail Yurtsever, Zuhal Gucin, Mesut Seker and Haci Mehmet Turk in Journal of Oncology Pharmacy Practice

Published
2021
Full Text
View/download PDF

22. sj-pdf-2-opp-10.1177_10781552211027931 - Supplemental material for A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer

Author

Topcu, Atakan, Yasin, Ayse Irem, Shbair, Abdallah TM, Besiroglu, Mehmet, Simsek, Melih, Sucuoglu, Zehra, Yurtsever, Ismail, Gucin, Zuhal, Seker, Mesut, and Turk, Haci Mehmet

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-pdf-2-opp-10.1177_10781552211027931 for A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer by Atakan Topcu, Ayse Irem Yasin, Abdallah TM Shbair, Mehmet Besiroglu, Melih Simsek, Zehra Sucuoglu, Ismail Yurtsever, Zuhal Gucin, Mesut Seker and Haci Mehmet Turk in Journal of Oncology Pharmacy Practice

Published
2021
Full Text
View/download PDF

23. Diffusion Tensor Imaging Can Discriminate the Primary Cell Type of Intracranial Metastases for Patients with Lung Cancer.

Author

Bilgin, Sabriye Sennur, Gultekin, Mehmet Ali, Yurtsever, Ismail, Yilmaz, Temel Fatih, Cesme, Dilek Hacer, Bilgin, Melike, Topcu, Atakan, Besiroglu, Mehmet, Turk, Haci Mehmet, Alkan, Alpay, and Bilgin, Mehmet

Subjects
LUNG cancer, BRAIN damage, CARCINOMA, ANISOTROPY, METASTASIS
Abstract

Purpose: Histopathological differentiation of primary lung cancer is clinically important. We aimed to investigate whether diffusion tensor imaging (DTI) parameters of metastatic brain lesions could predict the histopathological types of the primary lung cancer. Methods: In total, 53 patients with 98 solid metastatic brain lesions of lung cancer were included. Lung tumors were subgrouped as non-small cell carcinoma (NSCLC) (n = 34) and small cell carcinoma (SCLC) (n = 19). Apparent diffusion coefficient (ADC) and Fractional anisotropy (FA) values were calculated from solid enhanced part of the brain metastases. The association between FA and ADC values and histopathological subtype of the primary tumor was investigated. Results: The mean ADC and FA values obtained from the solid part of the brain metastases of SCLC were significantly lower than the NSCLC metastases (P < 0.001 and P = 0.003, respectively). ROC curve analysis showed diagnostic performance for mean ADC values (AUC=0.889, P = < 0.001) and FA values (AUC = 0.677, P = 0.002). Cut-off value of > 0.909 × 10-3 mm²/s for mean ADC (Sensitivity = 80.3, Specificity = 83.8, PPV = 89.1, NPV = 72.1) and > 0.139 for FA values (Sensitivity = 80.3, Specificity = 54.1, PPV = 74.2, NPV= 62.5) revealed in differentiating NSCLC from NSCLC. Conclusion: DTI parameters of brain metastasis can discriminate SCLC andNSCLC. ADC and FA values of metastatic brain lesions due to the lung cancer may be an important tool to differentiate histopathological subgroups. DTI may guide clinicians for the management of intracranial metastatic lesions of lung cancer. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. Diffusion Tensor Imaging Can Discriminate the Primary Cell Type of Intracranial Metastases for Patients with Lung Cancer

Author

Bilgin, Sabriye Sennur, primary, Gultekin, Mehmet Ali, additional, Yurtsever, Ismail, additional, Yilmaz, Temel Fatih, additional, Cesme, Dilek Hacer, additional, Bilgin, Melike, additional, Topcu, Atakan, additional, Besiroglu, Mehmet, additional, Turk, Haci Mehmet, additional, Alkan, Alpay, additional, and Bilgin, Mehmet, additional

Published
2021
Full Text
View/download PDF

28. A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer.

Author

Topcu, Atakan, Yasin, Ayse Irem, Shbair, Abdallah TM, Besiroglu, Mehmet, Simsek, Melih, Sucuoglu, Zehra, Yurtsever, Ismail, Gucin, Zuhal, Seker, Mesut, and Turk, Haci Mehmet

Subjects
*DISEASE progression, *PATIENT aftercare, *PREDNISOLONE, *PROTEIN kinase inhibitors, *LIVER, *METASTASIS, *HEPATITIS, *LUNG tumors, *MAGNETIC resonance imaging, *BONE tumors, *HEPATOTOXICOLOGY, *AMINOTRANSFERASES, *BREAST tumors, *BILIRUBIN
Abstract

Introduction: Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. Case Report: A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently. Management & Outcome : Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. Discussion: Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results